Co-acting gene networks predict TRAIL responsiveness of tumour cells with high accuracy

Paul O'Reilly, Csaba Ortutay, Grainne Gernon

  • 1Apoptosis Research Centre, National University of Ireland Galway, University Rd, Galway, Ireland. eva.szegezdi@nuigalway.ie.

BMC Genomics
|December 21, 2014
PubMed
Abstract

Insights

This study reveals that gene interactions, not just differential expression, are key to predicting tumor cell response to TRAIL therapy. Identifying co-acting gene clusters offers a more accurate method for predicting treatment sensitivity.

Area of Science:

  • Cancer biology
  • Genomics
  • Bioinformatics

Background:

  • Differential gene expression is commonly used to find tumor biomarkers.
  • This method is limited in identifying gene interactions that dictate drug response.
  • Biological responses are better described by component relationships than absolute expression.

Purpose of the Study:

  • To identify genes and their functional relationships that predict sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
  • To develop a more accurate predictor of TRAIL sensitivity by analyzing gene interactions.

Main Methods:

  • Used gene expression microarray data from 109 tumor cell lines.
  • Applied Random Forest machine learning and backward elimination for predictor identification.
  • Assessed gene co-regulation, statistical interaction, and functional interactions using q-order partial correlation and Ingenuity network analysis.

Main Results:

  • A gene panel accurately predicted TRAIL sensitivity (AUC=0.84).
  • Co-regulated genes showed functional interactions in cell death, survival, and differentiation pathways.
  • Only 12% of predictor genes were differentially expressed, emphasizing the role of functional interactions.

Conclusions:

  • Co-acting gene cluster analysis is independent of differential expression and captures gene interactions.
  • This approach identified a superior predictor of TRAIL sensitivity and potential novel regulators.
  • The study provided insights into the molecular differences between TRAIL-sensitive and resistant cell types.

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.6K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

4.4K
Protein Networks02:26

Protein Networks

An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
4.7K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
8.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.8K